{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:33:48Z","timestamp":1792492428326,"version":"4.5.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer cells in B cell malignancies, such as multiple myeloma (MM). It is a second-generation CAR that is outfitted with an ectodomain comprising two BCMA-binding single chain variable fragment (ScFv) domains, a transmembrane domain, and an endodomain possessing CD3\u03b6 and 4-1BB. Cilta-cel is an autologous, gene-edited CAR T-cell that is prepared by collecting and modifying the recipient\u2019s T-cells to create a patient personalized treatment in the laboratory to be infused back. This CAR T-cell product exceptionally entails CARs with two BCMA-targeting single-domain antibodies that detect two epitopes of BCMA expressed on the malignant cells of MM. Cilta-cel is the current addition to the treatment armamentarium of relapsed or refractory (r\/r) MM after its approval by the FDA on February 28, 2022, based on the results of the Phase 1b\/2 CARTITUDE-1 study. It was the second approved anti-BCMA CAR T-cell product after idecabtagene vicleucel (ide-cel) to treat myeloma patients. It induces early, deep, and long-lasting responses with a tolerable safety profile in r\/r MM. Cilta-cel-treated myeloma patients may potentially experience adverse effects ranging from mild to life-threatening, but they are mostly manageable toxicities. Besides, it has a consistent safety profile upon a longer follow-up of patients. Cilta-cel generally outperforms ide cel in terms of efficacy in MM, but shows comparable adverse events. This review highlights the current updates on cilta-cel efficacy, adverse events, comparison with ide-cel, and its future direction in the treatment of MM.<\/jats:p>","DOI":"10.3389\/fimmu.2022.991092","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T09:27:36Z","timestamp":1662110856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":106,"title":["Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma"],"prefix":"10.3389","volume":"13","author":[{"given":"Endeshaw","family":"Chekol Abebe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mestet","family":"Yibeltal Shiferaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitalew","family":"Tadele Admasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadesse","family":"Asmamaw Dejenie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"B1","first-page":"277","article-title":"Adoptive immunotherapy for b-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells","volume":"9","author":"Park","year":"2010","journal-title":"Discov Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-019-0789-z","article-title":"Chimeric antigen receptor\u2013engineered T cell therapy in lymphoma","volume":"21","author":"Strati","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(96)80078-1","article-title":"Human tumor antigens recognized by T cells","volume":"8","author":"Robbins","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"B5","article-title":"Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity","volume":"21","author":"Gross","year":"1989","journal-title":"Transplant Proc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-t-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering car-t cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive cellular therapies: the current landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Archiv"},{"key":"B9","article-title":"The global pipeline of cell therapies for cancer","volume":"18","author":"Yu","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood J Am Soc Hematology."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a b-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.03.002","article-title":"CARs and other T cell therapies for MM: The clinical experience","volume":"31","author":"Danhof","year":"2018","journal-title":"Best Pract Res Clin Haematology."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric antigen receptor-modified T cell therapy in multiple myeloma: Beyond b cell maturation antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2013challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"44179","DOI":"10.18632\/oncotarget.6175","article-title":"Therapeutic potential of CAR-T cell-derived exosomes: A cell-free modality for targeted cancer therapy","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting b cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple b-cell maturation antigen\u2013expressing hematological malignances by anti-b-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B20","article-title":"TNFRSF17 (tumor necrosis factor receptor superfamily, member 17)","volume":"19","author":"Gillespie","year":"2015","journal-title":"Org"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: A systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood J Am Soc Hematology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum b-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple MyelomaAnti-BCMA chimeric antigen receptor","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"key":"B27","article-title":"US Food and drug administration approves Bristol Myers squibb\u2019s and bluebird bio\u2019s abecma (idecabtagene vicleucel), the first anti-bcma car T cell therapy for relapsed or refractory multiple myeloma. abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple survival","volume":"5","author":"Wire","year":"2021"},{"key":"B28","volume-title":"FDA Approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma","year":"2022"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-t-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12772","article-title":"T Cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: More room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: A new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"14001","DOI":"10.1038\/mtm.2014.1","article-title":"Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors","volume":"1","author":"Jin","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B38","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood J Am Soc Hematology."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy","volume":"111","author":"Hinrichs","year":"2008","journal-title":"Blood J Am Soc Hematology."},{"key":"B40","first-page":"4038","article-title":"Fueling chimeric antigen receptor T cells with cytokines","volume":"10","author":"Jin","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncol"},{"key":"B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against b cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/blood-2021-146060","article-title":"Updated results from CARTITUDE-1: phase 1b\/2Study of ciltacabtagene autoleucel, a b-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1182\/blood-2021-146072","article-title":"Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a b-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: Updated results from CARTITUDE-2","volume":"138","author":"Cohen","year":"2021","journal-title":"Blood"},{"key":"B45","article-title":"Editors. updated results of cartitude-2: Ciltacabtagene autoleucel (cilta-cel), a b-cell maturation antigen (BCMA)\u2013directed chimeric antigen receptor T cell (CAR-T) therapy, in lenalidomide-refractory patients with progressive multiple myeloma (MM) after 1\u20133 prior lines of therapy. 2022 tandem meetings| transplantation & cellular therapy meetings of ASTCT and CIBMTR","author":"Hillengass","year":"2022","journal-title":"Tandem Meetings"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000829604.35383.e8","article-title":"P08: CARTITUDE-2 UPDATE: Ciltacabtagene autoleucel, a b-cell maturation antigen\u2013directed chimeric antigen receptor T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy","volume":"6","author":"Einsele","year":"2022","journal-title":"HemaSphere"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843632.57974.e8","article-title":"Cartitude-2 cohort b: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy","volume":"6","author":"Agha","year":"2022","journal-title":"Euripean Heamtol Assoc"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/01.HS9.0000829568.10814.bc","article-title":"B07: Safety and efficacy of ciltacabtagene autoleucel, a chimeric antigen receptor t-cell therapy directed against b-cell maturation antigen in patients with multiple myeloma and early relapse after initial therapy: cartitude-2 results","volume":"6","author":"van de Donk","year":"2022","journal-title":"HemaSphere"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.thorsurg.2014.12.003","article-title":"National comprehensive cancer network (NCCN) clinical practice guidelines for lung cancer screening","volume":"25","author":"Wood","year":"2015","journal-title":"Thorac Surg clinics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-140243","article-title":"Chimeric antigen receptor T cell therapy in the relapsed or refractory multiple myeloma with extramedullary disease\u2013a single institution observation in china","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a b-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B53","first-page":"8005","article-title":"Ciltacabtagene autoleucel, a b-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1","volume":"39","author":"Usmani","year":"2021","journal-title":"Wolters Kluwer Health"},{"key":"B54","article-title":"CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy","volume":"39","author":"Agha","year":"2021","journal-title":"Wolters Kluwer Health"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with b-cell acute lymphoblastic LeukemiaBiomarkers of neurotoxicity in CD19 CAR T cell therapy","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"B58","volume-title":"FDA Approves idecabtagene vicleucel for multiple myeloma","year":"2021"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.17925\/OHR.2022.18.1.59","article-title":"Novel therapies in BCMA-exposed Relapsed\/Refractory multiple myeloma: The anti-BCMA therapy-refractory patient","volume":"18","author":"Golden","year":"2022","journal-title":"touchREVIEWS Oncol Haematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02101-7","article-title":"OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa","volume":"21","author":"Anderson","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin","year":"2021","journal-title":"Curr Med Res Opinion"},{"key":"B65","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2514","article-title":"Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials","volume":"36","author":"Mangal","year":"2018","journal-title":"Hematol Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136360","article-title":"Cytokine release syndrome in patients with relapsed\/refractory multiple myeloma treated with ciltacabtagene autoleucel in the phase 1b\/2 CARTITUDE-1 study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"B70","article-title":"A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against b-cell maturation antigen (BCMA) in participants with multiple myeloma (CARTITUDE-2)","year":"2022","journal-title":"ClinicalTrialsgov"},{"key":"B71","volume-title":"Janssen research and development l. CARVYKTI- CARTITUDE-4 (MMY3002) study","year":"2022"},{"key":"B72","article-title":"Nct04923893: phase 3 - bort\/len\/dex f\/b cilta-cel f\/b len\/dex ndmm- (no asct planned) cartitude-5","author":"Education","year":"2021","journal-title":"Myeloma Clin trials"},{"key":"B73","volume-title":"Janssen research and development l. CARVYKTI- CARTITUDE-6 (MMY3005) study","year":"2022"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti\u2013b-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor\u2013redirected T cells against multiple MyelomaLenalidomide enhances function of CS1 CAR T cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.991092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T09:28:00Z","timestamp":1662110880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.991092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2022.991092"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.991092","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"article-number":"991092"}}